

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10591347
Filing Date	2009-03-18
First Named Inventor	Yardena SAMUELS et al.
Art Unit	1642
Examiner Name	TBD
Attorney Docket Number	001107.00617

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5846824		1998-12-08	Hiles et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	01/16306	WO		2001-03-08	Innis		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****(Not for submission under 37 CFR 1.99)**

Application Number	10591347
Filing Date	2009-03-18
First Named Inventor	Yardena SAMUELS et al.
Art Unit	1642
Examiner Name	TBD
Attorney Docket Number	001107.00617

1	L. ZHANG ET AL., "The Oncogene Phosphatidylinositol 3' Kinase Catalytic Subunit Alpha Promotes Angiogenesis via Vascular Endothelial Growth Factor in Ovarian Carcinoma," Cancer Research, July 15, 2003, Vol. 63, No. 14, pp. 4225-4231	<input type="checkbox"/>
2	Y-Y MA ET AL., "PIK3CA as an Oncogene in Cervical Cancer," Oncogene, May 25, 2000, Vol. 19, No. 23, pp. 2739-2744	<input type="checkbox"/>
3	K. HILL ET AL., "Specific Requirement for the p85-p110alpha Phosphatidylinositol 3-Kinase During Epidermal Growth Factor-Stimulated Actin Nucleation in Breast Cancer Cells," Journal of Biological Chemistry, February 11, 2000, Vol. 275, No. 6, pp. 3741-3744	<input type="checkbox"/>
4	S. DAO ET AL., "Antisense Inhibition of PIK3CA Reverses Cancer Phenotype," Proceedings of the Annual meeting of the American Association for Cancer Research, March 1, 2002, Vol. 43, p. 602	<input type="checkbox"/>
5	P. RODRIGUEZ-VICIANA ET AL., "Activation of Phosphoinositide 3-Kinase by Interaction with RAS and by Point Mutation," EMBO Journal, January 1, 1996, Vol. 15, No. 10, pp. 2442-2451	<input type="checkbox"/>
6		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.